Who are LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PIFLUFOLASTAT, 18F-rhPSMA-7.3, [Ga-68]PSMA, piflufolastat (18F), Lu-177 PSMA-617, [18F]PSMA-PET.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lutetium-lu-177-vipivotide-tetraxetan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand Therapeutic Agent [EPC].

marketed Radioligand Therapeutic Agent [EPC] PSMA Recombinant protein Live · refreshed every 30 min

Target snapshot

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN). Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN TARGET	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01
PIFLUFOLASTAT	PIFLUFOLASTAT		marketed	Radioactive Diagnostic Agent [EPC]	PSMA	2021-01-01
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
piflufolastat (18F)	piflufolastat (18F)	Blue Earth Diagnostics	marketed	PSMA-targeting PET imaging agent	PSMA (prostate-specific membrane antigen)
Lu-177 PSMA-617	Lu-177 PSMA-617	Radboud University Medical Center	phase 3	Radioligand therapy	PSMA (prostate-specific membrane antigen)
[18F]PSMA-PET	[18F]PSMA-PET	Region Västerbotten	phase 3		PSMA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radioligand Therapeutic Agent [EPC] class)

· 1 drug in this class
Aaa Usa Novartis · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN — Competitive Intelligence Brief. https://druglandscape.com/ci/lutetium-lu-177-vipivotide-tetraxetan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab